TLR4 recombinant proteins and antibodies

Toll-like receptor 4 (TLR4) is a member of the Toll-like receptor family that plays a crucial role in the immune system. Located on the cell surface, it can recognize exogenous pathogens and endogenous damage signals. TLR4, through its interaction with bacterial lipopolysaccharides (LPS), activates the immune system’s inflammatory response. The activation process involves multiple signaling pathways, including the MyD88-dependent and TRIF-dependent pathways, which initiate the expression of inflammatory genes through key transcription factors like NF-κB. TLR4’s activation not only plays a critical role in innate immunity but also has a significant influence on the regulation of adaptive immune responses.

TLR4 is closely associated with the development of various diseases, including bacterial infections, sepsis, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Due to its key role in immune responses, TLR4 has become an important target for drug development across multiple fields. Drug development targeting TLR4 focuses on two main strategies: one is inhibiting its excessive activation, which leads to inflammation, and the other is activating TLR4 to enhance immune responses, particularly in cancer immunotherapy.

In the development of TLR4 inhibitors, researchers are developing TLR4 antagonists, especially for the treatment of inflammatory diseases such as sepsis and rheumatoid arthritis. These drugs work by blocking the binding of TLR4 to LPS, reducing inflammatory responses and tissue damage. Additionally, TLR4 agonists are also under development, aiming to activate TLR4 and enhance the immune system’s ability to fight diseases, particularly in cancer immunotherapy.
Several biopharmaceutical companies have made significant progress in TLR4-targeted research and drug development. For instance, companies like Apexigen are developing TLR4 agonists for use in cancer immunotherapy. Other companies, including Novartis and Bayer, are conducting clinical trials on TLR4 antagonists to assess their efficacy in treating immune-mediated diseases. With ongoing research, TLR4-targeted therapies are expected to provide new therapeutic options for a variety of diseases.

To assist in the development of TLR4 targeted drugs, DIMA BIOTECH can now provide a series of spot products targeting TLR4, including TLR4 recombinant proteins, TLR4 full-length membrane proteins, anti-TLR4 monoclonal antibodies and biosimilar reference antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank targeting TLR4, which can screen out the lead antibody molecules required by customers in just 20 days.